预约演示
更新于：2025-09-27
Mometasone Furoate
糠酸莫米松
更新于：2025-09-27
概要
基本信息
权益机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C27H30Cl2O6 |
InChIKeyWOFMFGQZHJDGCX-ZULDAHANSA-N |
CAS号83919-23-7 |
关联
289
项与 糠酸莫米松 相关的临床试验ChiCTR2500109003
Efficacy Evaluation of Omalizumab Injection in Patients with Uncontrolled Perennial Moderate-to-Severe Allergic Rhinitis: A Multicenter, Randomized, Open-Label, Investigator-Initiated Study （OPERA Study）
CTR20253045
单中心、随机、开放、单次给药的糠酸莫米松乳膏人体生物等效性研究(药代动力学对比研究/初步剂量持续时间-效应研究/关键生物等效性研究)
NCT07114107
Evaluation of the Efficacy and Safety of Vibroacoustic Therapy With Oscillating Positive Expiratory Pressure in the Treatment of Nasal Congestion: A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Clinical Trial
100 项与 糠酸莫米松 相关的临床结果
登录后查看更多信息
100 项与 糠酸莫米松 相关的转化医学
登录后查看更多信息
100 项与 糠酸莫米松 相关的专利（医药）
登录后查看更多信息
1,819
项与 糠酸莫米松 相关的文献（医药）2026-01-01JOURNAL OF ETHNOPHARMACOLOGY
Yu-Ping-Feng nasal drops relieve allergic rhinitis via TRPV1/Ca2+/NFAT pathway
Article
作者: Hu, Yucheng ; Ren, Qiuyi ; Luo, Hongping ; Li, Junjie ; Tian, Li ; Wang, Xiaobo ; Wang, Fu ; Fu, Linyou
ETHNOPHARMACOLOGICAL RELEVANCE:
Allergic rhinitis (AR) is a chronic inflammatory disorder of the nasal mucosa mediated by immunoglobulin E (IgE). Yu-Ping-Feng nasal drops (YPFND), a compound derived from traditional Chinese medicine, is extensively utilized in the management of respiratory ailments, including AR. Nonetheless, the precise biological pathways through which YPFND influences AR are yet to be fully elucidated.
PURPOSE:
We aim to investigate the bioactivity of YPFND against AR and its therapeutic potential molecular mechanism.
METHODS:
We conducted a 14-day randomized controlled trial involving 60 AR patients assigned to control group (10 % YPFND solution, Con group), mometasone furoate group (MFN group), and YPFND group, with nasal symptom outcomes assessed post-treatment. In parallel, an ovalbumin (OVA)- developed AR rat model was established to investigate the effect of YPFND on nasal mucosal inflammation. Nasal tissues and serum were analyzed by ELISA, Western blot, quantitative PCR (qPCR), histology, immunofluorescence and flow cytometry. Chemical constituents of YPFND were identified via LC-MS/MS. Serum proteomics in control and OVA-induced AR rats was analyzed by nano-HPLC-MS/MS with DIA-NN identification and MaxLFQ quantification. Molecular docking and molecular dynamics (MD) simulations were performed to predict the binding affinity of active compounds to the transient receptor potential vanilloid 1 (TRPV1) protein. In vitro, human nasal epithelial cells (HNEpC) were stimulated with interleukin-17 A (IL-17 A) to induce inflammation. The effects of YPFND on TRPV1-mediated Ca2+ influx and nuclear factor of activated T cells (NFAT) activation were assessed, and TRPV1 specificity was confirmed using the antagonist SB-366791.
RESULTS:
LC-MS/MS analysis identified 984 compounds, among which molecular docking revealed nine candidates exhibiting strong binding affinity to TRPV1. Subsequently, MD simulations confirmed the stability of the 5-O-methylvisammioside-TRPV1 complex. Quantitative proteomics quantified 9978 proteins and identified 527 significantly altered proteins (259 upregulated, 268 downregulated) between OVA-induced AR and control rats, enriched in pathways including inflammatory mediator regulation of TRP channels. YPFND significantly alleviated clinical and experimental AR symptoms. In HNEpC, IL-17 A stimulated the expression of TRPV1 and facilitated Ca2+ influx. YPFND inhibited the IL-17 A-provoked NFAT expression via the TRPV1/Ca2+ signaling pathway. In addition, YPFND ameliorated airway inflammation by inhibiting the TRPV1/NFAT pathway in AR rats and down-regulated the expression of retinoic acid receptor-related orphan receptor gamma t (RORγ-t), further regulating the balance between T helper 17 (Th17) cells and regulatory T (Treg) cells.
CONCLUSION:
Our research elucidates a novel IL-17A/TRPV1/Ca2+/NFAT signaling cascade as a critical mediator of Th17/Treg disequilibrium in AR. Moreover, it demonstrates that YPFND exerts anti-inflammatory effects by attenuating TRPV1-dependent Ca2+ influx and its downstream NFAT activation.
2025-10-01RESPIRATORY MEDICINE
Efficacy and safety of novel fixed dose combination of vilanterol, glycopyrronium, and fluticasone furoate dry powder inhaler: A phase 3, randomized, non-inferiority trial compared with fixed dose combination of indacaterol, glycopyrronium, and mometasone furoate dry powder inhaler in Indian asthma patients
Article
作者: Pathak, Hardik ; Jain, Manish Kumar ; Sahoo, Diptikant ; Parmar, Deven ; Bhate, Amit S ; Kumar, Avadhesh ; Shrivastava, Rahul ; Koppula, Ravi ; Patel, Chintan ; Kansagra, Kevinkumar ; Sheth, Vaishal ; Mondal, Asish
BACKGROUND:
For managing persistent asthma, M/s. Zydus Healthcare Limited has developed a novel fixed dose combination (FDC) of vilanterol 25 μg, glycopyrronium 50 μg, and fluticasone furoate 200 μg (VIL-GLY-FF) in dry powder inhaler (DPI) formulation.
METHODS:
This phase 3, multicenter, parallel group, open-label study randomized (1:1) patients not controlled with medium or high-dose inhaled corticosteroid in either the test (VIL-GLY-FF DPI) or reference (approved FDC DPI of indacaterol 150 μg, GLY 50 μg, and mometasone furoate 160 μg [IND-GLY-MF]) group. FDCs were administered by inhaling one capsule via Respihaler device once-daily for 12 weeks. The primary endpoint was the change in trough forced expiratory volume in 1 s (FEV1) at week 12 from baseline. Secondary outcomes included the comparison of trough forced vital capacity (FVC), post-bronchodilator FEV1 and FVC, and asthma control test score between the two groups.
FINDINGS:
All 256 enrolled patients completed the study. The least square mean (standard error) change in trough FEV1 at week 12 from baseline was 392.77 (31.33) ml and 364.34 (31.33) ml for the test and reference groups (p = 0.522), respectively. The lower limit of 95 % confidence interval for the difference between two groups for the mean change in trough FEV1 at week 12 from baseline was -58.83 ml, well-above the predefined non-inferiority margin (-150 ml). Other secondary endpoints and safety were comparable between the two groups.
INTERPRETATION:
VIL-GLY-FF DPI was found non-inferior to IND-GLY-MF DPI in improving trough FEV1 response. The test FDC was well-tolerated in Indian patients with persistent asthma.
CLINICAL TRIAL REGISTRATION NUMBER:
CTRI/2024/02/063046 (Clinical Trial Registry - India).
2025-09-16JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Stapokibart for Severe Uncontrolled Chronic Rhinosinusitis With Nasal Polyps
Article
Importance:
Chronic rhinosinusitis with nasal polyps causes severe symptoms and impaired quality of life. Stapokibart is a novel monoclonal antibody that targets interleukin 4Rα.
Objective:
To assess the efficacy and safety of stapokibart as an add-on treatment to intranasal corticosteroids in patients with severe uncontrolled chronic rhinosinusitis with nasal polyps.
Design, Setting, and Participants:
From August 9, 2022, to April 28, 2023, this randomized, double-blind, phase 3 clinical trial, conducted at 51 hospitals in China, enrolled adult patients with chronic rhinosinusitis with nasal polyps who had a history of systemic corticosteroid use or sinonasal surgery and a bilateral nasal polyp score of 5 or greater (on a scale of 0-8) and a weekly mean nasal congestion score of 2 or greater (on a scale of 0-3). Eosinophilic chronic rhinosinusitis with nasal polyps was defined as blood eosinophils of 6.9% or greater (without asthma) or 3.7% or greater (with asthma) or an eosinophil count of 55 per high-power field or greater or 27% or greater in nasal polyp tissue. Patient follow-up was completed on June 25, 2024.
Interventions:
Four weeks after initiation of mometasone furoate nasal spray, 100 µg in each nostril daily, patients were randomized to receive subcutaneous stapokibart, 300 mg, or placebo (1:1) every 2 weeks for 24 weeks. Both groups then received stapokibart for 28 weeks.
Main Outcomes and Measures:
Co–primary end points were changes from baseline in nasal polyp score (meaningful change threshold [MCT] ≥1 point) and nasal congestion score (MCT ≥0.5 points) at week 24 in all patients and in the population with eosinophilia.
Results:
Among 180 patients randomized, 179 (mean age, 45 [SD, 12.9] years; 61 [34.1%] women) received at least 1 treatment dose (n = 90 for stapokibart; n = 89 for placebo). In the overall population, the least-squares (LS) mean change in nasal polyp score from baseline to week 24 in the stapokibart vs placebo groups was −2.6 vs −0.3 points, respectively, (LS mean difference, −2.3; 95% CI, −2.6 to −1.9; P < .001); in the population with eosinophilia, the change was −3.0 vs −0.4 points, respectively (LS mean difference, −2.5; 95% CI, −2.9 to −2.1; P < .001). The LS mean change in nasal congestion score from baseline to week 24 in the stapokibart vs placebo groups was −1.2 vs −0.5 points, respectively, in the overall population (LS mean difference, −0.7; 95% CI, −0.9 to −0.5; P < .001) and −1.3 vs −0.5 points, respectively, in the population with eosinophilia (LS mean difference, −0.8; 95% CI, −1.0 to −0.6; P < .001). Serious adverse events were rare (2.2% in the stapokibart group vs 1.1% in the placebo group). Higher rates of arthralgia (7.8% vs 0%) and hyperuricemia (5.6% vs 1.1%) were reported with stapokibart vs placebo, respectively.
Conclusions and Relevance:
Among patients with severe chronic rhinosinusitis with nasal polyps treated with a daily intranasal corticosteroid, stapokibart reduced polyp size and severity of nasal symptoms at 24 weeks.
Trial Registration:
ClinicalTrials.gov Identifier: NCT05436275
100 项与 糠酸莫米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 慢性鼻窦炎伴鼻息肉 | 美国 | 2017-12-08 | |
| 哮喘 | 美国 | 2005-03-30 | |
| 鼻息肉 | 美国 | 2004-12-15 | |
| 瘙痒（皮肤发痒） | 巴西 | 2003-08-28 | |
| 过敏性鼻炎 | 中国 | 2000-07-14 | |
| 皮炎 | 中国 | 1999-01-01 | |
| 常年性变应性鼻炎 | 美国 | 1997-10-01 | |
| 季节性过敏性鼻炎 | 美国 | 1997-10-01 | |
| 斑秃 | 日本 | 1993-10-01 | |
| 药物性皮炎 | 日本 | 1993-10-01 | |
| 湿疹 | 日本 | 1993-10-01 | |
| 渗出性红斑 | 日本 | 1993-10-01 | |
| 红皮病性银屑病 | 日本 | 1993-10-01 | |
| 脓疱疮 | 日本 | 1993-10-01 | |
| 瘢痕疙瘩 | 日本 | 1993-10-01 | |
| 盘状红斑狼疮 | 日本 | 1993-10-01 | |
| 大疱性类天疱疮 | 日本 | 1993-10-01 | |
| 糠疹 | 日本 | 1993-10-01 | |
| 痒疹 | 日本 | 1993-10-01 | |
| 银屑病 | 日本 | 1993-10-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性鼻窦炎 | 临床3期 | 美国 | 2022-01-24 | |
| 常年性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 季节性鼻炎 | 临床3期 | 中国 | 2019-04-10 | |
| 打喷嚏 | 临床3期 | 阿根廷 | 2012-10-01 | |
| 鼻粘膜充血 | 临床3期 | - | 2008-07-01 | |
| 间歇性哮喘 | 临床3期 | - | 2008-05-01 | |
| 腺样体肥大 | 临床3期 | - | 2007-08-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-09-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | - | 2006-09-01 | |
| 持续性哮喘 | 临床3期 | - | 2006-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 59 | ESO-101 800 µg | 獵顧顧獵鏇憲顧鏇簾遞(衊壓積簾鬱壓鬱膚遞鑰) = 糧壓築簾蓋衊餘願廠鹹 願構糧憲築餘簾憲淵餘 (鹽鹹醖鹽製願憲遞艱夢, 88.42) 更多 | 积极 | 2024-10-13 | ||
Placebo | 獵顧顧獵鏇憲顧鏇簾遞(衊壓積簾鬱壓鬱膚遞鑰) = 構簾齋選鑰鏇顧膚選網 願構糧憲築餘簾憲淵餘 (鹽鹹醖鹽製願憲遞艱夢, 65.11) 更多 | ||||||
临床1期 | 16 | (Mometasone 1mg) | 築顧範鏇齋淵襯糧憲繭(夢鏇膚選衊鬱鬱壓壓衊) = 膚廠蓋衊簾壓範淵鬱糧 製齋鬱糧積顧願願願鹹 (蓋簾鬱積鹽淵選襯糧糧, 蓋構廠願餘網蓋遞淵淵 ~ 積鏇繭壓夢衊繭簾衊獵) 更多 | - | 2024-08-12 | ||
(Mometasone 2mg) | 築顧範鏇齋淵襯糧憲繭(夢鏇膚選衊鬱鬱壓壓衊) = 網觸築衊膚鑰範襯構觸 製齋鬱糧積顧願願願鹹 (蓋簾鬱積鹽淵選襯糧糧, 餘鏇願壓鏇鹽憲範遞廠 ~ 淵鹽齋襯願艱顧艱網簾) 更多 | ||||||
临床2期 | 43 | 選壓構積遞艱糧鑰選鏇(鹹醖繭壓願齋廠廠繭襯) = met with a statistically significant reduction of the peak eosinophil count (p=0.0318) compared to placebo. 醖選網製鏇餘鹹鏇醖壓 (選艱膚襯積廠鑰衊遞鏇 ) | 积极 | 2023-12-05 | |||
placebo | |||||||
临床2期 | 71 | (LYR-210 (Low Dose)) | 蓋獵網選衊齋鑰淵艱襯(簾網構鬱艱窪獵齋鬱鬱) = 蓋淵鬱構醖遞範襯願醖 顧廠鏇蓋積鏇願鹹網製 (蓋觸壓憲繭鑰觸獵繭選, 0.637) 更多 | - | 2023-06-06 | ||
(LYR-210 (High Dose)) | 蓋獵網選衊齋鑰淵艱襯(簾網構鬱艱窪獵齋鬱鬱) = 築範衊醖獵鏇願觸蓋襯 顧廠鏇蓋積鏇願鹹網製 (蓋觸壓憲繭鑰觸獵繭選, 0.651) 更多 | ||||||
临床4期 | 53 | (Mometasone Furoate Nasal Irrigation) | 醖夢廠顧窪壓築壓顧製(範廠窪範構壓鏇淵獵鑰) = 襯廠觸觸襯築齋遞範範 淵糧積顧積鹹夢鑰襯餘 (餘構獵壓窪鬱壓糧糧憲, 鬱蓋願遞壓蓋繭衊製蓋 ~ 繭構鏇簾鏇壓網網鏇鹹) 更多 | - | 2020-12-19 | ||
(Mometasone Nasal Spray) | 醖夢廠顧窪壓築壓顧製(範廠窪範構壓鏇淵獵鑰) = 願製築壓選積憲夢選夢 淵糧積顧積鹹夢鑰襯餘 (餘構獵壓窪鬱壓糧糧憲, 觸網遞壓積衊廠艱獵淵 ~ 糧襯蓋餘蓋襯餘壓獵襯) 更多 | ||||||
临床3期 | 880 | (NASONEX® Nasal Spray (Schering Corporation)) | 簾襯壓鹹顧鹹鬱築鹽憲(鹽鬱憲願築醖壓壓構鏇) = 餘壓觸襯淵齋顧顧積襯 齋齋齋製襯鹽廠廠範窪 (繭襯齋夢壓遞製廠繭醖, 2.186) 更多 | - | 2020-08-19 | ||
(Mometasone Nasal Spray (Watson Laboratories, Inc)) | 簾襯壓鹹顧鹹鬱築鹽憲(鹽鬱憲願築醖壓壓構鏇) = 淵積製淵壓夢遞觸襯夢 齋齋齋製襯鹽廠廠範窪 (繭襯齋夢壓遞製廠繭醖, 2.223) 更多 | ||||||
N/A | 739 | Mometasone furoate 80 μg (Breezhaler®) | 遞壓鹽糧積獵夢製艱齋(範簾網窪鹽鏇衊蓋艱憲) = 築選糧淵壓築憲鏇齋鬱 網醖網顧蓋觸觸鬱鏇鹽 (膚壓網壓淵獵築壓襯遞, -34 ~ 89) | - | 2020-06-01 | ||
临床3期 | 802 | indacaterol acetate+mometasone furoate | 網積鹹範憲築鹹獵選範(醖膚醖繭窪淵蓋鬱壓鑰): LSMD = 0.182, P-Value = <0.001 更多 | 积极 | 2020-01-01 | ||
临床3期 | 50 | 窪窪淵簾繭鹽鹽顧鏇選 = 夢繭夢窪築糧繭壓夢觸 壓簾顧衊蓋積糧糧糧襯 (蓋網膚選積蓋鹽顧鑰築, 選餘衊鹹願製鏇醖衊衊 ~ 選鹹糧網衊願鑰構衊願) 更多 | - | 2019-11-27 | |||
临床2期 | - | IND/GLY/MF o.d. 150/50/160 μg | 願鹹顧糧鏇糧壓簾鬱繭(鑰築網選範鏇積餘廠淵) = 觸遞廠艱網簾獵繭範積 鏇顧壓遞蓋衊鹹選鹹構 (鹹遞夢蓋鏇齋膚願築淵, 66 ~ 142) 更多 | - | 2019-09-28 | ||
IND/GLY/MF o.d. 150/50/80 μg | 願鹹顧糧鏇糧壓簾鬱繭(鑰築網選範鏇積餘廠淵) = 築淵衊獵選窪糧顧鬱廠 鏇顧壓遞蓋衊鹹選鹹構 (鹹遞夢蓋鏇齋膚願築淵, 48 ~ 125) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用